Ristomycin monosulfate

≥90% ristocetin A basis (balance primarily Ristocetin B)

Ristocetin sulfate salt
Empirical Formula (Hill Notation):
C95H110N8O44 · H2SO4
CAS Number:
Molecular Weight:
MDL number:
PubChem Substance ID:

Quality Level


≥90% ristocetin A basis (balance primarily Ristocetin B)

Mode of action

cell wall synthesis | interferes

storage temp.


SMILES string




InChI key


Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

Ristomycin/ristocetin is a type III glycopeptide. It is a highly glycosylated glycopeptide, previously found in Amycolatopsis lurida.


Ristomycin monosulfate has been used:
  • to activate platelet and induce platelet aggregation
  • to study the aggregation responses of platelets from buffalo, horse, pig and sheep
  • in in-house ristocetin cofactor von Willebrand factor (VWF:RCo) assay to measure glycoprotein Ib (GpIb) binding activity


100, 250 mg in poly bottle

Biochem/physiol Actions

Ristocetin activates platelets. Ristocetin-induced platelet agglutination (RIPA) is decreased in patients undergoing chronic hemodialysis. Together with increased plasma glycocalicin levels (a product of enzymatic cleavage of GPIb), RIPA may contribute to diminished platelet adhesion to vascular subendothelium and increased bleeding associated with uremia. Addition of ristocetin and vWf caused specific agglutination of rGPIbα-liposomes suporting the potential use of rGPIbα-liposomes to enhance platelet function in vivo and support hemostasis in thrombocytopenic individuals.
Ristomycin possesses antibacterial activity. It may be used to diagnose von Willebrand disease and Bernard-Soulier syndrome. Ristocetin-induced platelet agglutination (RIPA) is decreased in patients undergoing chronic hemodialysis. Increased plasma glycocalicin levels (a product of enzymatic cleavage of GPIb) and decreased RIPA might reduce platelet adhesion to vascular subendothelium and improve bleeding associated with uremia in patients with chronic hemodialysis.

Other Notes

Glycopeptide antibiotic complex

Personal Protective Equipment

dust mask type N95 (US),Eyeshields,Gloves


NONH for all modes of transport

WGK Germany


Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis

Certificate of Origin

Novel antibodies against GPIb alpha inhibit pulmonary metastasis by affecting vWF-GPIb alpha interaction
Qi Y, et al.
Journal of Hematology & Oncology, 11(1), 117-117 (2018)
Jordan, D.C. et al.
Antibiotics, 1, 84-84 (1967)
Bleeding Symptoms and von Willebrand Factor Levels: 30-Year Experience in a Tertiary Care Center
Moonla C, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis (2019)
Elevated plasma glycocalicin levels and decreased ristocetin-induced platelet agglutination in hemodialysis patients
Himmelfarb J, et al.
American Journal of Kidney Diseases, 32(1), 132-138 (1998)
Species variability in platelet aggregation response to different agonists
Pelagalli A, et al.
Journal of Comparative Pathology, 127(2-3), 126-132 (2019)
Related Content
We offer agonists, antagonists, modulators and other bioactive small molecules for immune system signaling target identification and validation, as well as a variety of antibiotics, antivirals, and antifungals.
Read More

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.